Above we have shown the analgesics, Mundipharma markets in Denmark.

Pain relief to improve quality of life

Pain is not a disease, but a critical warning function. For example, up to 90 % of all cancer patients experience pain as their illness progresses.1 Mundipharma is behind a number of analgesic medicines each adapted to different kinds of pain – e.g. acute pain, chronic pain and cancer pain.

Pain can also be caused by damage and disease in connective tissues, muscles, bones, tendons, the nervous system and the internal organs. Treatment depends on the type of pain and its severity, and relief can be provided by e.g tablets under the tongue, tablets, capsules, dissolutions for injection and analgesic patches.

Corporate social responsibility – opioid

At Mundipharma we are committed to developing a diverse portfolio of medicines and devices that meet societal needs. We aim to conduct our business in an ethical, transparent and responsible way, doing what’s right for our employees and partners, while contributing to the communities within which we operate. We look at things from a different perspective and are experts at identifying and developing the potential of medical innovations to help improve patient’s lives in meaningful ways.

Our responsibility in opioid management

We have a proud, 35-year heritage in pain management across Europe and are committed to enabling healthcare professionals to treat their patients in pain safely and responsibly.

As an organisation that sells opioids, we believe we have a responsibility to take measures to minimise the risk of misuse and abuse of these medicines while not depriving the patients that need them.

We recognize that misuse and abuse of pain medications can lead to addiction, overdose and death, and we are aware of the public health risk these potent medications can create, especially when they are diverted, misused and/or abused. That’s why we are committed to reducing the risk of misuse and abuse through a secure supply chain, appropriate education of healthcare professionals, responsible sales and marketing and close collaboration with government authorities and medical organisations.

We fund educational initiatives in line with industry regulations that clearly communicate the facts about opioid medicines in a balanced and responsible manner, outlining both risks and benefits and helping to ensure that our medicines are prescribed only to the right patient for the right reasons.

We are also committed to finding new approaches to the management of pain, including research into new mechanisms and medicines with the potential to reduce or avoid the need for opioids.

In Europe, heroin and opioid addiction is an emerging problem in our communities, and the population is often overlooked. We are encouraged that our medicines also play an important role in addiction rehabilitation treatment programmes to help this underserved community.

1. Hrachya Nersesyan, Konstantin V Slavin.Ther Clin Risk Manag. 2007 Jun; 3(3): 381–400.

 

This site is intended for Danish audiences only.

Norspan®

Obtain information about Norspan® here:

Min medicin

Product leaflet

Product summary

 

This site is intended for Danish audiences only.

OxyContin®

Obtain information about OxyContin® here:

Min medicin

Product leaflet

Product summary

 

This site is intended for Danish audiences only.

OxyNorm®

Obtain information about OxyNorm® here:

Min medicin

Product leaflet

Product summary

 

This site is intended for Danish audiences only.

Palladon®

Obtain information about Palladon® here:

Min medicin

Product leaflet

Product summary

 

This site is intended for Danish audiences only.

Targin®

Obtain information about Targin® here:

Min medicin

Product leaflet

Product summary

 

This site is intended for Danish audiences only.

Todolac®

Obtain information about Todolac® here:

Min medicin

Product leaflet

Product summary

 

This site is intended for Danish audiences only.

Transtec®

Obtain information about Transtec® here:

Min medicin

Product leaflet

Product summary

 

This site is intended for Danish audiences only.

© 2018 Mundipharma A/S

Address

Mundipharma A/S
Frydenlundsvej 30, Building E,
2950 Vedbæk - Denmark

Contact

Phone: +45 45 17 48 00
Fax: +45 45 17 48 29
Monday - Friday at 9.00 - 16.00
mundipharma@mundipharma.dk

About Mundipharma

Mundipharma A/S is a part of Purdue/Mundipharma/Napp, which is an international network of independent associated medical companies.

Conditions for the use of Mundipharma.dk